Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918577 | 1.00 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2GLP1RTSHR | |
| SCHEMBL6918510 | 1.00 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2GLP1RTSHR | |
| SCHEMBL24598210 | 0.93 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL6919398 | 0.93 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL23007708 | 0.89 | LMNA (0.33) | MEN1KMT2ACYP2C19KDM4E | |
| SCHEMBL23158646 | 0.88 | KDM4E (0.43) | MEN1KMT2ASMN1; SMN2TSHRHPGD | |
| SCHEMBL21673583 | 0.88 | TSHR (0.41) | MEN1KMT2ASMN1; SMN2TSHRHPGD | |
| SCHEMBL23838529 | 0.88 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2GLP1RTSHR | |
| SCHEMBL21025904 | 0.88 | TSHR (0.41) | MEN1KMT2ASMN1; SMN2TSHRHPGD | |
| SCHEMBL21172203 | 0.88 | ALDH1A1 (0.41) | MEN1KMT2ASMN1; SMN2GLP1RTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-9556250-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-01-31 | — | — | US | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| EP-3000482-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2016-03-30 | — | — | EP | disclosed |
| EP-2513140-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2015-11-04 | — | — | EP | disclosed |
| EP-2932981-A2 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK A/S (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-06-26 | — | — | US | disclosed |
| US-8648041-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2014-02-11 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NORDISK A/S (DK) | 2012-12-27 | — | — | US | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
| WO-2011080103-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | FABP1, FABP2, FABP4 | MEN1 4838/4885KMT2A 4645/4885SMN1; SMN2 2383/4885 |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, GCG | MEN1 447/4885KMT2A 459/4885SMN1; SMN2 3840/4885 |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | GLP1R, GIPR, IAPP | MEN1 680/4885KMT2A 4238/4885SMN1; SMN2 3474/4885 |
| US-20160108102-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | MEN1 680/4885KMT2A 4238/4885SMN1; SMN2 3474/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | MEN1 680/4885KMT2A 4238/4885SMN1; SMN2 3474/4885 |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, GCG, DPP7 | MEN1 641/4885KMT2A 184/4885SMN1; SMN2 3814/4885 |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | GLP1R, GIPR, GCGR | MEN1 2118/4885KMT2A 3213/4885SMN1; SMN2 4231/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | MEN1 1830/4885KMT2A 4343/4885SMN1; SMN2 3794/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | MEN1 680/4885KMT2A 4238/4885SMN1; SMN2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.